Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Mauss, S ^a   Berger, F ^a   Schober, A ^b   Moog, G ^c   Heyne, R ^d   John, C ^e   Pape, S ^f   Hueppe, D ^g   Pfeiffer Vornkahl, H ^h   Alshuth, U ⁱ  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b Center for Gastroenterology   (Germany)

^c Center for Gastroenterology   (Germany)

^d Center for Gastroenterology and Liver Center   (Germany)

^e Center for Gastroenterology   (Germany)

^f Center for Gastroenterology   (Germany)

^g Center of Gastroenterology   (Germany)

^h Scientific Information and Communication MbH   (Germany)

ⁱ ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

antimitochondrial antibodies; antinuclear antibodies; autoantibodies; hepatitis C; liver kidney microsomal antibodies; smooth muscle antibodies

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; SMOOTH MUSCLE ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSICIAN; PRIORITY JOURNAL; THYROID DISEASE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84875231429     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12011     Document Type: Article

References (15)

1. Wasmuth HE, Stolte C, Geier A, et al,. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4: 4.
2. Garrido Palma G, Sánchez Cuenca JM, Olaso V, et al,. Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies. Rev Esp Enferm Dig 1999; 91: 168-181.
3. Yee LJ, Kelleher P, Goldin RD, et al,. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004; 11: 459-464.
4. Narciso-Schiavon JL, Freire FC, Suarez MM, et al,. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009; 21: 440-446.
5. Chen CH, Lee CM, Chen CH, et al,. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 2010; 33: 258-265.
6. Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL,; Trent HCV Group. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 2009; 16: 325-331.
7. Muratori P, Muratori L, Guidi M, et al,. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501-507.
8. Bai L, Feng ZR, Lu HY, Li WG, Yu M, Xu XY,. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 2009; 122: 5-9.
9. Ferri S, Muratori L, Quarneti C, et al,. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009; 50: 1093-1101.
10. Monti V, Aghemo A, Rumi MG, Donato MF, Del Ninno E, Colombo M,. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005; 10: 715-720.
11. Duclos-Vallée JC, Nishioka M, Hosomi N, et al,. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol 1998; 28: 965-970.
12. Cassani F, Cataleta M, Valentini P, et al,. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-566.
13. Todros L, Saracco G, Durazzo M, et al,. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-1378.
14. Sarrazin C, Berg T, Ross RS, et al,. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289-351.
15. Manns MP, Rambusch EG,. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31 (Suppl 1): 39-42.